Research advances in cirrhotic cardiomyopathy / 临床肝胆病杂志

ABSTRACT

Cirrhotic cardiomyopathy (CCM) refers to the abnormalities in cardiac structure and function in patients with liver cirrhosis. The pathogenesis of CCM involves the apoptosis of cardiomyocytes, impaired β-receptors, and increased levels of cardiodepressant factors such as nitric oxide, carbon monoxide, endocannabinoids, bacterial endotoxins, and inflammatory mediators. At present, there are no unified diagnostic criteria for CCM, and a clinical diagnosis can be made based on clinical manifestation, plasma brain natriuretic peptide, N-terminal pro-brain natriuretic peptide, electrocardiographic findings, ultrasound findings, and the results of cardiac magnetic resonance imaging. The treatment of CCM involves controlling liver cirrhosis and protecting the myocardium, and the best therapeutic method is liver transplantation at the right time.